

# AXID (2020-04-29)

Report a Concern  
(<http://www.healthycanadians.gc.ca/report-signalez/index-eng.php>)

<b>Starting date:</b>	April 29, 2020
<b>Type of communication:</b>	Drug Recall
<b>Subcategory:</b>	Drugs
<b>Hazard classification:</b>	Type I
<b>Source of recall:</b>	Health Canada
<b>Issue:</b>	Product Safety
<b>Audience:</b>	General Public, Healthcare Professionals, Hospitals
<b>Identification number:</b>	RA-72959

Last updated: 2020-05-04

## Summary

- **Product:** AXID 150 mg Capsules

- [Reason](#)
- [Depth of distribution](#)
- [Affected products](#)

## Reason

Presence of N-nitrosodimethylamine (NDMA) near the interim acceptable concentration limit in affected lots

## Depth of distribution

Wholesalers, Retailers, Healthcare establishments

## Affected products

AXID 150 mg Capsules

DIN, NPN, DIN-HIM

DIN 00778338

Dosage form

Capsule

Strength

Nizatidine 150 mg

Lot or serial number

616927, 617088

Companies

### Recalling Firm

Pendopharm Division of Pharmascience Inc.  
SUITE 100 6111, Royalmount Avenue  
Montreal  
H4P 2T4  
Quebec  
CANADA

**Marketing Authorization Holder** Pendopharm Division of Pharmascience Inc.  
SUITE 100 6111, Royalmount Avenue  
Montreal  
H4P 2T4  
Quebec  
CANADA

**For more information**

<https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72963a-eng.php> (<https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72963a-eng.php>)

**Date modified:** 2020-05-04